Promising drug combo aims to wipe out bladder cancer before surgery

NCT ID NCT07314723

Recruiting now Disease control Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Jun 14, 2026 · Updated 21 times

Summary

This study tests whether combining two drugs (9MW2821 and toripalimab) before and after surgery can improve outcomes for people with urothelial cancer (a type of bladder cancer). About 90 adults with non-spread cancer will receive the treatment and be monitored for tumor shrinkage and safety. The goal is to see if this approach can eliminate visible cancer and delay or prevent recurrence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

transitional cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CARCINOMA